These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

548 related articles for article (PubMed ID: 36284349)

  • 1. Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy.
    Zhao B; Li H; Xia Y; Wang Y; Wang Y; Shi Y; Xing H; Qu T; Wang Y; Ma W
    J Hematol Oncol; 2022 Oct; 15(1):153. PubMed ID: 36284349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B7-H3/CD276: An Emerging Cancer Immunotherapy.
    Zhou WT; Jin WL
    Front Immunol; 2021; 12():701006. PubMed ID: 34349762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B7-H3 in Brain Malignancies: Immunology and Immunotherapy.
    Guo X; Chang M; Wang Y; Xing B; Ma W
    Int J Biol Sci; 2023; 19(12):3762-3780. PubMed ID: 37564196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy.
    Picarda E; Ohaegbulam KC; Zang X
    Clin Cancer Res; 2016 Jul; 22(14):3425-3431. PubMed ID: 27208063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B7-H3, a checkpoint molecule, as a target for cancer immunotherapy.
    Yang S; Wei W; Zhao Q
    Int J Biol Sci; 2020; 16(11):1767-1773. PubMed ID: 32398947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. To kill a cancer: Targeting the immune inhibitory checkpoint molecule, B7-H3.
    Kanchan RK; Doss D; Khan P; Nasser MW; Mahapatra S
    Biochim Biophys Acta Rev Cancer; 2022 Sep; 1877(5):188783. PubMed ID: 36028149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B7-H3 immunoregulatory roles in cancer.
    Mortezaee K
    Biomed Pharmacother; 2023 Jul; 163():114890. PubMed ID: 37196544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B7-H3: An Attractive Target for Antibody-based Immunotherapy.
    Kontos F; Michelakos T; Kurokawa T; Sadagopan A; Schwab JH; Ferrone CR; Ferrone S
    Clin Cancer Res; 2021 Mar; 27(5):1227-1235. PubMed ID: 33051306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B7-H3-mediated tumor immunology: Friend or foe?
    Wang L; Kang FB; Shan BE
    Int J Cancer; 2014 Jun; 134(12):2764-71. PubMed ID: 24013874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New frontiers in immune checkpoint B7-H3 (CD276) research and drug development.
    Getu AA; Tigabu A; Zhou M; Lu J; Fodstad Ø; Tan M
    Mol Cancer; 2023 Mar; 22(1):43. PubMed ID: 36859240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B7-H3 at the crossroads between tumor plasticity and colorectal cancer progression: a potential target for therapeutic intervention.
    Varghese E; Samuel SM; Brockmueller A; Shakibaei M; Kubatka P; Büsselberg D
    Cancer Metastasis Rev; 2024 Mar; 43(1):115-133. PubMed ID: 37768439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A promising target for breast cancer: B7-H3.
    Jiang Y; Liu J; Chen L; Qian Z; Zhang Y
    BMC Cancer; 2024 Feb; 24(1):182. PubMed ID: 38326735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B7-H3-targeted CAR-T cell therapy for solid tumors.
    Li G; Wang H; Wu H; Chen J
    Int Rev Immunol; 2022; 41(6):625-637. PubMed ID: 35855615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of B7-H3 in tumors and its potential in clinical application.
    Feng R; Chen Y; Liu Y; Zhou Q; Zhang W
    Int Immunopharmacol; 2021 Dec; 101(Pt B):108153. PubMed ID: 34678689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B7-H3 Immune Checkpoint Protein in Human Cancer.
    Flem-Karlsen K; Fodstad Ø; Nunes-Xavier CE
    Curr Med Chem; 2020; 27(24):4062-4086. PubMed ID: 31099317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of B7-H3, a potential factor of tumor immune evasion in combination with the number of regulatory T cells, affects against recurrence-free survival in breast cancer patients.
    Maeda N; Yoshimura K; Yamamoto S; Kuramasu A; Inoue M; Suzuki N; Watanabe Y; Maeda Y; Kamei R; Tsunedomi R; Shindo Y; Inui M; Tamada K; Yoshino S; Hazama S; Oka M
    Ann Surg Oncol; 2014 Dec; 21 Suppl 4(Suppl 4):S546-54. PubMed ID: 24562936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B7-H3 role in the immune landscape of cancer.
    Castellanos JR; Purvis IJ; Labak CM; Guda MR; Tsung AJ; Velpula KK; Asuthkar S
    Am J Clin Exp Immunol; 2017; 6(4):66-75. PubMed ID: 28695059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble B7-CD28 Family Inhibitory Immune Checkpoint Proteins and Anti-Cancer Immunotherapy.
    Khan M; Arooj S; Wang H
    Front Immunol; 2021; 12():651634. PubMed ID: 34531847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New checkpoints in cancer immunotherapy.
    Ni L; Dong C
    Immunol Rev; 2017 Mar; 276(1):52-65. PubMed ID: 28258699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B7-H3 on circulating epithelial tumor cells correlates with the proliferation marker, Ki-67, and may be associated with the aggressiveness of tumors in breast cancer patients.
    Pizon M; Schott DS; Pachmann U; Pachmann K
    Int J Oncol; 2018 Nov; 53(5):2289-2299. PubMed ID: 30226585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.